In the present study we explored potential protein biomarkers useful to predict the therapeutic response of osteoarthritis (OA) patients treated with pharmaceutical grade Chondroitin sulfate/Glucosamine hydrochloride (CS+GH; Droglican, Bioiberica), in order to optimize therapeutic outcomes.